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Characterization and quantification of the fungal
microbiome in serial samples from individuals
with cystic fibrosis
Sven D Willger1, Sharon L Grim2,4, Emily L Dolben1, Anna Shipunova2, Thomas H Hampton1, Hilary G Morrison2,
Laura M Filkins1, George A O‘Toole1, Lisa A Moulton3, Alix Ashare3, Mitchell L Sogin2 and Deborah A Hogan1*
Abstract
Background: Human-associated microbial communities include fungi, but we understand little about which fungal
species are present, their relative and absolute abundances, and how antimicrobial therapy impacts fungal communities.
The disease cystic fibrosis (CF) often involves chronic airway colonization by bacteria and fungi, and these infections
cause irreversible lung damage. Fungi are detected more frequently in CF sputum samples upon initiation of
antimicrobial therapy, and several studies have implicated the detection of fungi in sputum with worse outcomes.
Thus, a more complete understanding of fungi in CF is required.
Results: We characterized the fungi and bacteria in expectorated sputa from six CF subjects. Samples were collected
upon admission for systemic antibacterial therapy and upon the completion of treatment and analyzed using a
pyrosequencing-based analysis of fungal internal transcribed spacer 1 (ITS1) and bacterial 16S rDNA sequences. A
mixture of Candida species and Malassezia dominated the mycobiome in all samples (74%–99% of fungal reads). There
was not a striking trend correlating fungal and bacterial richness, and richness showed a decline after antibiotic therapy
particularly for the bacteria. The fungal communities within a sputum sample resembled other samples from that
subject despite the aggressive antibacterial therapy. Quantitative PCR analysis of fungal 18S rDNA sequences to assess
fungal burden showed variation in fungal density in sputum before and after antibacterial therapy but no consistent
directional trend. Analysis of Candida ITS1 sequences amplified from sputum or pure culture-derived genomic DNA
from individual Candida species found little (<0.5%) or no variation in ITS1 sequences within or between strains,
thereby validating this locus for the purpose of Candida species identification. We also report the enhancement of the
publically available Visualization and Analysis of Microbial Population Structures (VAMPS) tool for the analysis of fungal
communities in clinical samples.
Conclusions: Fungi are present in CF respiratory sputum. In CF, the use of intravenous antibiotic therapy often does
not profoundly impact bacterial community structure, and we observed a similar stability in fungal species
composition. Further studies are required to predict the effects of antibacterials on fungal burden in CF and fungal
community stability in non-CF populations.
* Correspondence: dhogan@dartmouth.edu
1Geisel School of Medicine at Dartmouth, Hanover, NH, USA
Full list of author information is available at the end of the article
© 2014 Willger et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Willger et al. Microbiome 2014, 2:40
http://www.microbiomejournal.com/content/2/1/40
Background
Subjects with the genetic disease cystic fibrosis (CF)
often have complex, chronic mixed bacterial-fungal lung
infections that cause severe lung damage that can pro-
gress to respiratory failure. Molecular profiling studies
strongly support a model in which CF lung infections
contain multiple bacteria [1-3], and recent work has re-
vealed that these communities are often surprisingly
stable within subjects over time [2,4-7]. Fungal species,
such as Candida albicans and Aspergillus fumigatus, are
also commonly detected in sputum cultures. Culture-
based studies have detected C. albicans in ~40%–75%
CF subjects [8-21] and described its association with re-
duced lung function [16,22]. A large European study
found that the presence of fungi by laboratory culture
correlated with a 5%–10% lower lung function in CF
[20]. Two prospective studies have linked the detection
of either C. albicans or A. fumigatus to lower lung func-
tion and increased frequency of disease exacerbations
[16,22]. Other fungi have also been detected in the CF
lung [19,23-27]. Challenges associated with the culturing
of fungi, due to slow growth, specific medium require-
ments [28], and the lack of quantitative methods due in
part to filamentous morphologies [29], have made it dif-
ficult to describe fungal species and their relative bur-
dens in the CF lung. Consequently, despite data that
suggest that the mycobiome poses a health threat to in-
dividuals with CF [16,22], there is not yet a comprehen-
sive standard of care upon the detection of fungi in
sputum.
Individuals with CF-associated lung infections usually
experience periods of stable lung function interspersed
with episodes of disease exacerbation, which is loosely de-
fined as a period of impaired lung function or the worsen-
ing of other health metrics that requires hospitalization
for the administration of one or more intravenous antibi-
otics. The effects of antibiotic treatment on bacterial num-
bers and community structure are not fully understood
and variable across subjects. One recent study found that
antibiotic therapy does not cause reproducible shifts in
bacterial community structure or bacterial density within
sputum [30], while another study reported that antibiotic
use was associated with decreased diversity and
short-term shifts in community structure [4]. The effects of
antibiotic therapy on fungal loads or fungal species com-
position in the lung are not well known. Several studies
have indicated that antibiotic usage precedes the increased
detection of fungi in sputum [31-36]. Furthermore, anti-
biotic therapy in other systems correlates with an increased
incidence of fungal infections, such as bloodstream infec-
tions [37-40], oral candidosis [41], and vaginal candidiasis
[42], and increased fungal loads in the gastrointestinal tract
[43-45]. A full characterization of the fungal species within
sputum and other host-associated microbial communities
will require the community-wide implementation of lysis
methods that are effective for all bacterial and fungal spe-
cies and the use of a combination of molecular methods
that provide information on all of the species present. Most
molecular analyses of host-associated fungi have relied
upon amplification and sequencing of the internal tran-
scribed spacer 1 (ITS1) region within the ribosomal RNA
operon [46-49]. Due to a high degree of variation between
even closely related species [50-52], this region can serve as
a unique taxonomic identifier in both traditional capillary
and next generation DNA sequencing studies [46-49].
In this report, we assessed the fungi within the CF lung
in subjects hospitalized for treatment with antibacterial
antibiotics and advanced the development of tools for the
analysis of the fungal component of the microbiome
(mycobiome) within clinical samples. Using primers that
amplify the ITS1 region, we characterized the mycobiome
and bacterial microbiome in expectorated sputum samples
from six subjects before and after antibiotic therapy.
Candida species dominated the mycobiomes, and their
relative abundances were stable over time in contrast to
less stable bacterial community structures. Using these
samples, we also quantified the numbers of fungal ge-
nomes within each sample and found variability in how
fungal densities in sputum changed over time and after
treatment with antibacterial drugs. Lastly, towards facili-
tating future mycobiome studies, we assess intra-strain
variability in Candida ITS1 sequences and describe im-
provement of the fungal ITS1 reference database associ-
ated with VAMPS (Visualization and Analysis of Microbial
Population Structures) [53] and its use in analyses of fungal
ITS1 sequences amplified from host-associated microbial
communities.
Results
Adapting a publicly available tool for mycobiome analysis
To aid the analysis of fungal ITS1 sequences, particularly
those amplified from clinical samples, we improved the
ITS reference database for Global Alignment for Sequence
Taxonomy (GAST) [54] analyses within VAMPS, a widely
used web-based tool [53] that resolves phylogenetic affin-
ity of marker gene sequences from diverse bacterial com-
munities ([2,55-57] as examples). The reference database
for assigning the taxonomic affinity of fungal ITS1 ampli-
con sequences derives from the UNITE database [58].
Our modifications included a number of corrections to
the taxonomic information within records for medically
relevant fungi, and the removal of some sequences that
were exact matches to well-characterized plant sequences
that had been incorrectly annotated as being of fungal ori-
gin. We also increased representation of the human-
associated fungi Candida and Malassezia in the database
by adding all Genbank database entries that contained the
keywords “ITS”, “Candida”, and “Malassezia” and had
Willger et al. Microbiome 2014, 2:40 Page 2 of 15
http://www.microbiomejournal.com/content/2/1/40
complete annotations. This step increased the number of
Candida species from 251 to 284 and the number of
unique accession IDs containing the keyword “Candida”
from 930 to 2021. For Malassezia, 72 unique accession
IDs containing the keyword “Malassezia” from Genbank
with complete genus and species information were added.
Overall assessment of the fungi identified in sputum from
inpatient subjects
Using VAMPS, we analyzed the fungal community in CF
sputum from six hospitalized subjects that received
subject-specific antibacterial treatments (Additional file 1:
Table S1). Using primers that match conserved flanking
sequences, we PCR-amplified the fungal ITS1 sequences
from sputum DNA samples for pyrosequencing analyses.
We determined the reproducibility of the fungal ITS1
amplification and deep sequencing protocol by analyzing
technical replicate libraries created from the same DNA
that had been extracted from a de-identified sputum sam-
ple collected for the purposes of the method development.
The results from the two technical replicates were very
similar in terms of the fraction of reads assigned to each
fungus (<1% difference in percent abundance per sample)
(Additional file 2: Figure S1).
Datasets from each sputum sample contained an
average of 21,434 fungal reads ranging from 1,672 fun-
gal reads (the inter-treatment sample of subject #9)
and 37,684 (the post-treatment sample of subject #6)
(Additional file 3: Table S3), and a rarefaction analysis
indicated that the sequencing depth was sufficient to
detect the vast majority of fungi present (Additional
file 4: Figure S2A). Candida represented the dominant
genus with 11 different species. The top three Candida
species (C. albicans, Candida dubliniensis, and Candida
parapsilosis) accounted for 74%–99.9% of all ITS1 reads
in all samples (Figure 1A) making these species both the
Figure 1 Characterization of the fungal communities of sputum samples from CF subjects. (A) Fraction of pyrosequencing reads assigned
to each of the top four fungal taxa detected in CF subjects immediately after an exacerbation and before starting an antibacterial therapy (pre)
and approximately 2 weeks afterwards (post) or while hospitalized (inter). The legend indicates the color assigned to each indicated fungal
species or genus (Malassezia sp. unknown). (B) Relative abundance of all fungal genera, extended to the species level for the clinically important
Candida species (colored dots), is plotted against the prevalence of each genus and Candida species in the six CF subject samples (pre- and
post-treatment) and show that fungi that are highly abundant in a single patient are also highly prevalent across patients. The colored dots
indicate the Candida species and the genus Malassezia that are both highly abundant and highly prevalent and the empty dots represent all
remaining fungal genera identified in our study.
Willger et al. Microbiome 2014, 2:40 Page 3 of 15
http://www.microbiomejournal.com/content/2/1/40
most abundant species and also the most prevalent. C.
albicans ranged from 0.1% of reads (the post-treatment
sample from subject #2) to 98.8% of reads (the post-
treatment sample from subject #6) (Additional file 5:
Table S4). In three subjects, the only reported fungi
using culture-based detection methods were C. parapsi-
losis in subjects #1 and #3 and C. dubliniensis in sub-
ject #2 (Additional file 1: Table S1). Another clinically
interesting Candida species, Candida tropicalis, was
detected at lower levels, ranging from 2 to 477 reads,
and only in half of the samples (Figure 1B). Aside from
C. albicans, only Malassezia spp. (including Malassezia
restricta and Malassezia globosa) occurred in all sam-
ples, but at levels 10- to 50-fold lower than the Can-
dida spp. reads (Figure 1A,B). We detected low
numbers of reads corresponding to three different spe-
cies of Aspergillus (Aspergillus unguis, Aspergillus versi-
color, and Aspergillus sp.) in this study, but not A.
fumigatus, another common CF pathogen, which we
have previously detected in other CF sputum samples
(data not shown). Across all 14 samples, our VAMPS-
based analyses detected 111 different taxa at the genus
level, and these resolved to 147 species level assign-
ments (Additional file 5: Table S4). The minor members
of the mycobiome are discussed in more detail below.
To validate the results obtained by GAST analyses, we
employed BLAST to assign fungal ITS1 sequences to
species and genus level categories (Additional file 6:
Table S5). For the BLAST searches, we batch blasted ex-
amples of all unique reads and assigned a genus or spe-
cies to each set of sequences. Comparison of GAST and
BLAST results initially highlighted the need for database
improvement (described above), and once the database
had been modified, the two methods yielded a similar
number of taxa. Because GAST reports the consensus
annotation for all of the sequences that match the query,
the developmental state of the ITS1 database may limit
the assignment of genus or species level information. In
this case, sequences clustered by GAST in VAMPS can
be easily retrieved for further analysis.
Because the characterization of fungi within host-
associated microbial communities is at an early stage, we
sought to determine if there were any ITS1 sequences
that have not been previously described. In initial ana-
lyses, up to 13.3% of sequences in a sample could not be
identified as fungi (BLAST scores of greater than e − 15
for the top hit). On average, samples had 3.6% of reads
in this category. Further analysis querying Genbank’s
Nucleotide collection (nr/nt) database revealed that
most of these unassigned sequences corresponded to
ITS1 sequences in the genomes of food-associated plants
such as Pisum sativum (peas), Allium cepa (onions), Al-
lium sativum (garlic), Solanum tuberosum (potato), and
Glycine max (soybean) suggesting contamination of the
sputum sample from subjects’ diets. The primers used to
amplify fungal ITS1 sequences (Additional file 7: Table S2)
displayed high levels of similarity to comparable regions in
plants. VAMPS allows one to limit analyses to specific
taxonomic levels or to specific groups (for instance, fungi
or Ascomycetes) [53], and this eliminated the problem of
contaminating sequences. A very small number of un-
assignable sequences (13 out of 300,072 reads) were also
identified, but they were most often single reads that were
only found within single samples and were not character-
ized further.
Comparison of intra- and inter-species ITS1 sequence
differences in Candida spp.
Some fungal genomes may contain up to 600 copies of
the ribosomal RNA genes (rDNA) and intraspecific ITS
variability can exceed 24.2% [59-62]. In contrast, C. albi-
cans typically has 150–200 copies of the ITS1 locus, with
one report estimating less than 0.2% ITS variability
within a strain [62]. Since Candida represented the pre-
dominant fungal genus in our CF subjects, we used Illu-
mina MiSeq sequencing to investigate levels of ITS1
sequence variation within and among clinical C. albicans
isolates. When the ITS1 region was amplified from gen-
omic DNA from pure cultures of C. albicans wild type
SC5314 and seven clinical isolates, then analyzed using
Illumina MiSeq, the predominant sequence (>99% of
reads) for each strain was the same (100% identical
across all isolates). The second most abundant sequence
accounted for only ~0.02% of reads. Similarly, we observed
no evidence for intra-strain variation in the ITS1 sequences
from the analysis of genomic DNAs isolated from pure cul-
tures of three other Candida species (C. dubliniensis, C.
parapsilosis, and C. kruseii) (data not shown).
When we compared the most abundant C. albicans
ITS1 sequence in the sputum-derived datasets to the
dominant sequence from the clinical isolates, we found
that they were 100% identical (data not shown). Align-
ments of the three most common ITS1 sequences that
resolved to C. albicans from each sample, with the ITS1
sequences from the genome information for C. albicans
strains SC5314 and WO-1, displayed 99% identity. The
second most abundant C. albicans ITS1 454 sequence
amplified from sputum DNA differed from the most
abundant ITS1 sequence by one missing “T” at position
60, which most likely reflects a 454 homopolymer se-
quencing error. By way of comparison, the closely re-
lated Candida species C. albicans and C. dubliniensis
have ITS1 sequences that have 94.6% identity.
Description of the mycobiome and bacterial microbiome
across serial sputum samples
In the collection of serial samples, each subject provided
a sputum sample at the time of admission for treatment
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of exacerbated respiratory disease using two or three an-
tibacterials and one sample upon the completion of
treatment; some subjects also provided a third sample
during treatment. The drugs administered included
Tobramycin, Vancomycin, Doripenem, Meropenem, Cef-
tazadime, and Linezolid and information which antibac-
terial drugs were used in each subject is provided in
Additional file 1: Table S1. The fungal communities in
all samples, grouped by subject, are shown in Figure 1A.
The relative abundance of reads corresponding to the
predominant Candida spp. appeared to be quite stable
over time during treatment, and there was no obvious
change upon treatment initiation (Figure 1A). Bray-Curtis
dissimilarity and principal coordinate analysis were used
to measure and represent taxonomic relatedness between
classes of samples in the mycobiome and the microbiome
samples. Antibiotic treatment did not establish a specific
fungal community. Fungal samples from unrelated people
at different points in therapy (unrelated, UNR) were no
more different than samples from unrelated people at the
same point in treatment (same treatment, STX). However,
mycobiome samples from the same subject (same sub-
ject, SPT) were significantly more similar to each other
(P <0.001) by a Tukey’s honest significant test (Figure 2A)
than mycobiome samples from the same treatment point,
suggesting that subjects’ fungal communities remained
relatively stable. Furthermore, as shown in the PCA scores
plot (Additional file 8: Figure S3), the samples from sub-
jects #1, #6, and #8 clustered together as did those from
subjects #2 and #9. Subject #3 was distinct from the other
samples (Additional file 8: Figure S3).
To compare the fungal community profiles to those
for the bacteria, we amplified and sequenced the V6 re-
gion of the bacterial 16S rDNA gene from the same
sputum DNA samples. On average, we recovered 726,787
sequences from each sample (Additional file 3: Table S3),
and a rarefaction analysis indicated that this deep sequen-
cing effort identified most members of the sampled
bacterial microbiomes (Additional file 4: Figure S2B).
Ninety-nine percent of all reads from all samples were
assigned to 44 genera, though not all 44 genera were
detected in every sample (Additional file 9: Table S6).
The remaining 1% of reads corresponded to 397 different
genera. As reported by other studies, most samples con-
tained high levels of the genera Pseudomonas, Staphylo-
coccus, Streptococcus, Prevotella, Rothia, Granulicatella,
Neisseria, Haemophilus, Porphyromonas, Gemella, and
members of the families Alcaligenaceae and Lachnospira-
ceae (Figure 3) [2,4,63,64].
Consistent with published work [4,6,65], the bacterial
community also displayed stability in the major commu-
nity members in many subjects (Figure 3), though some
changes in the bacteria with the highest relative abun-
dance were observed in subjects #2 and #6 (Figure 3).
The Bray-Curtis dissimilarity of the bacterial communi-
ties showed a less clear picture than for the fungi, but it
still was apparent that the samples from the same sub-
ject showed some degree of relatedness. Bacterial com-
munity profiles from the same subject were marginally
more similar (SPT) but the difference was not significant
by a Tukey’s honest significant test (Figure 2B); like for the
fungi, the STX samples were not more similar than the
UNR samples. There was less of a clear trend in sample
clustering in the PCA scores plot, and the larger number
of bacterial genera in each sample may have contributed
to this complexity (Additional file 8: Figure S3).
To compare bacterial and fungal richness across sam-
ples, we first accounted for differences in the number of
Figure 2 Relatedness of microbial communities. Box-and-whisker plots of pairwise Bray-Curtis distances of the mycobiome and microbiome
of cystic fibrosis (CF) subjects. (A) Fungal samples from unrelated subjects on different treatments (UNR) are no more different than samples from
unrelated subjects on the same treatments (STX). Mycobiome samples from the same subject (SPT) were significantly more similar to each other
(P <0. 001) by a Tukey’s honest significant test than mycobiome samples from the same treatment group, suggesting that patients’ fungal
communities are specific to patients and remain relatively stable during treatment. (B) Bacterial genera from the same subject (SPT) were
marginally more similar than unrelated subjects on different treatments (UNR) or unrelated subjects on the same treatments (STX) but these
differences were not significant by a Tukey’s honest significant test.
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reads by subsampling 1,000 reads for each fungal and
bacterial sample and repeatedly subsampling 1,000
times. First, we found that the normalized mean number
of fungal genera did not correlate with the number of
normalized mean bacterial genera (Figure 4). Using a
Wilcoxon matched-pairs signed ranked test, it was found
that the post-treatment samples had a lower mean bac-
terial genus richness (P <0.05) when compared to pre-
treatment samples (Additional file 10: Figure S4). While
the normalized mean richness for the fungi trended in
the same direction, the differences were not statistically
significant (P >0.1).
Analysis of minor members of the mycobiome
The remaining fungal genera represented relatively low
abundance populations that occurred in one or more
samples (Figure 1B and Additional file 5: Table S4 for
identities). When using the BLAST-based mycobiome
analysis (see Additional file 11), the number of taxa
identified within a sample ranged from 5 taxa (resolved
to 3 species, 1 genus, and 1 cluster of unidentified se-
quences in the post-treatment sample from subject #2)
to 60 taxa (resolved to 43 species, 16 genera, and 1 clus-
ter of unidentified sequences in the pre-treatment sam-
ple of subject #1) (Additional file 12: Table S5). Minor
members (<0.05% of annotated ITS1 sequences) of the
mycobiome included other Candida species, Trichos-
poron (an emerging pathogen in CF subjects [27,66]),
and the human pathogens Rhodotorula, Fusarium, and
Penicillium (Additional file 5: Table S4).
The deep sequencing in this study and the corre-
sponding rarefaction analyses suggest that we have iden-
tified the number of taxa that were common to the two
(and in some cases three) samples from a given subject
(Additional file 4: Figure S2). The overlap in fungal taxa in
samples from the same subject is presented as Euler and
Venn diagrams (Figure 5 based on data in Additional file 5:
Table S4). When only the pre- and post-treatment samples
were compared, an average of 44% ±19% of the fungal spe-
cies detected was common in both samples. This highlights
the fact that some of the minor fungal taxa were not com-
mon across the serial samples and may represent transient
species in the airway or oral community. As an example,
21 taxa were detected in both the pre-treatment and post-
treatment samples from subject #1; 34 taxa were unique to
the pre-treatment sample and 22 taxa were only in the
post-treatment sample (Figure 5). As sequencing depth
can impact the number taxa per sample and thus the
apparent stability of a taxon, we also considered and
presented the number of reads obtained for each sam-
ple; there were no differences in sequencing depth be-
tween the pre- and post-treatment samples from a
given subject (Figure 5). The stability of species across
Figure 3 Characterization of the bacterial communities of sputum samples from CF subjects. Fraction of reads assigned to each of the top
13 bacterial genera detected in CF subjects before treatment (pre), during treatment (inter), or after completion of treatment (post).
Figure 4 Comparison of fungal and bacterial richness within
samples. Scatter plot of the subsampled mean normalized number
of bacterial genera vs. the number of fungal genera found in the
sputum of CF subjects. Neither treatment nor high numbers of
bacterial or fungal genera have an obvious impact on each other.
The pre-treatment samples are depicted as circles, the intermediate
(inter) samples collected during treatment shown as triangles, and
the post-treatment samples are depicted squares. The colors represent
the different subjects.
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samples from the same subject was also assessed for
bacteria (Additional file 12: Figure S5). Again, compar-
ing the pre- and post-treatment samples, we found that
an average of 77% ±7% genera were in common in the
two samples (Additional file 12: Figure S5 based on
data in Additional file 9: Table S6). Additional file 13:
Table S7 highlights those fungal taxa, including low
abundance taxa that were detected in more than one
sample.
Analysis of the changes in community structure and
absolute abundance before and after antibacterial
therapy
To complement the data on the relative abundances
pre- and post-treatment, we also analyzed the density of
bacteria and fungi within each sputum sample by qPCR.
Results were normalized to sputum dry weight (genome
copies per mg dry weight) (Figure 6A). On average, we
could detect ~4.2 × 107 fungal genome copies/mg dry
Figure 5 Comparison of fungal communities in the same subject. Distribution of fungal taxa detected in CF subjects either immediately after
an exacerbation and before starting an antibacterial therapy (pre), approximately 2 weeks afterwards (post) or while hospitalized (inter) presented
in Euler diagrams for pre-post samples (subjects #1–6) and Venn diagrams for pre-inter-post samples (subjects #8 and 9) diagrams. The numbers
in parenthesis describe the total number of taxa detected in a sample; the numbers in the circles represent either the unique number of taxa in a
sample or the number of shared taxa in the overlap regions. The numbers in brackets represent the total number of reads for each sample.
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weight sputum with a maximum of 2.8 × 108 copies in
the post-treatment sample of subject #2 and minimum
of 2.9 × 105 copies in the post-treatment of subject #9
(Figure 6A). Overall, we did not observe a specific trend
in fungal burden corresponding to the antibacterial ther-
apy. In three subjects, the fungal burden dropped (sub-
jects #1, #6, and #9); in two subjects, the fungal density
increased (subjects #2 and #3); and subject #8 exhibited
no difference. We designed primers to quantify levels of
the four Candida species (Additional file 7: Table S2),
and the primers were shown to be species specific with
respect to one another in studies performed using gen-
omic DNA from purified cultures (data not shown).
When the absolute abundances of fungi, determined
using 18S rDNA quantification was compared to the
sum of the levels found using the Candida species
specific primer sets, they were within the same order of
magnitude (Additional file 14: Figure S6) confirming that
the Candida species were numerically dominant among
the fungi within these samples. The qPCR approach also
confirmed that relative abundance of C. tropicalis levels
was much lower than C. albicans (data not shown). This
finding may parallel observations that C. tropicalis is
often less abundant than the other Candida species in
oral samples [67-70].
We determined total bacterial burden without pre-
amplification by targeting the 16S rRNA locus [2]
(Figure 6B). On average, we detected ~9.2 × 108 bac-
terial genome copies/mg dry weight sputum with a
maximum of 1.1 × 1010 copies in the pre-treatment
sample of subject #2 and minimum of 4.0 × 105 copies
in the post-treatment of subject #2. As with the fungal
quantification, we did not observe a specific trend in
bacterial density in the pre- and post-treatment sam-
ples. The bacterial sputum density dropped in four of
the patients, most significantly in subject #2 in which
the bacterial burden within sputum dropped ~27,500-
fold to a level close to the detection limit. In two subjects,
the bacterial level went up approximately five-fold. There
was no correlation between the changes in bacterial dens-
ity and changes in fungal density (Figure 6).
Discussion
Dominant members of fungal communities, which we
defined as those that account for more than 80% of all
assigned reads per sample (Candida and Malassezia
species) (Figure 1A) persisted throughout treatment
without significant change in relative abundance sug-
gesting that there is stability within the mycobiome.
Many minor members of the fungal community ap-
peared to be ephemeral or sporadic, and thus did not
show changes in prevalence or abundance that could
be attributed to antibacterial treatment (Figure 5 and
Additional file 13: Table S7). Based on the depth of se-
quencing and the rarefaction analyses, the apparent in-
stability of minor members is unlikely an artifact of
sequencing depth, but rather likely a reflection of their
transient nature. The fungal species we detected within
CF sputum mirrors results in other recently published
work. For example, denaturing high-performance liquid
chromatography analysis of the ITS1 region amplified
from fungi within CF sputum also found C. albicans,
M. restricta and M. globosa [71]. In a study of four
stable CF subjects by Delhaes et al. [19], these fungi
were also well represented. While C. albicans is com-
monly observed in CF sputum, the presence of Malas-
sezia is less well understood in part because Malassezia
cannot be cultured without the use of specialized
medium. Investigation of the fungal communities on
the human skin found M. restricta and M. globosa to
Figure 6 Quantification of fungal and bacterial burden in CF
subjects. (A) Quantification of the fungal burden of sputum
samples from CF subjects. Total fungal burden was determined by
amplifying the 18S rDNA locus by qPCR. (B) Quantification of the
bacterial burden of sputum samples from cystic fibrosis subjects.
Total bacterial burden was determined by amplifying the 16 s rRNA
locus by real-time qPCR.
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be very common [72], and future work will be required
to determine if Malassezia are living in the lung or if
the signal is coming from dead cells or DNA. Mournier
et al. [71] also detected more fungi using molecular
methods when compared to culture-based analyses,
and Candida and Malassezia were among them. In
addition, they found that A. fumigatus was detected by
culture in some samples but not by molecular tech-
niques [71]. While A. fumigatus was not seen in clinical
microbiological analyses of the sputa in this study, we
were surprised by its complete absence from our data-
sets. We have detected A. fumigatus in other samples
indicating that our methods can amplify its ITS1 region.
A recent shotgun metagenomic analysis of CF sputum
DNA also found significant levels of C. albicans and A.
fumigatus by culture but found no DNA evidence for A.
fumigatus and a small number of other Candida se-
quences [73]. In contrast to what was observed in CF spu-
tum, Charlson et al. [74] analyzed the fungi in the lavages
of healthy individuals, and they found that healthy volun-
teers’ bronchoalveolar lavage (BAL) yielded scant fungal
amplification. Although Candida was identified in several
healthy subjects’ oropharyngeal washes, it was absent in
their BAL.
In this study, we explored whether inpatient treatment,
which included multiple antibacterials, impacted the
fungal community in a consistent way, perhaps indicat-
ing changes in biological niches or environmental condi-
tions upon perturbation of the bacterial community.
Our data suggest that the use of multiple antibiotics did
not necessarily have strong effects on either the bacterial
or fungal communities. While the number of bacterial
genera (richness) declined slightly but significantly
(Additional file 10: Figure S4), there was not a consistently
change to the structure of the community with similar
relative abundances of dominant species in four out of six
subjects (Figure 2 and Additional file 12: Figure S5). In
these same samples, we did not observe a consistent in-
crease in the number of fungal genera (Additional file 10:
Figure S4) and the fungal species that dominated the sam-
ples did not change markedly (Figure 1A). This lack of dif-
ference between pre- and post-samples may well be due to
the fact that these subjects have been exposed to years of
inhaled and intravenous antibacterial therapy, and the bac-
teria in their lungs have adapted or evolved in this context.
Thus, future studies in subjects without routine exposure
to antibiotics are needed in order to assess the effects of
antibacterials on the resident fungi. We and others have
characterized the interactions between Pseudomonas aer-
uginosa and C. albicans, including effects on fungal
morphology [75,76], viability [77,78], metabolism [76,79],
and virulence factor regulation [80,81], and the high rela-
tive abundance of P. aeruginosa in the bacterial communi-
ties and C. albicans in the fungal communities supports
the hypothesis that these species have the potential to im-
pact one another in the lung.
The therapy used in the treatment of disease exacerba-
tion also had no consistent impact on fungal density in
patient sputum samples. Measurements of fungal and
bacterial genomes per milligram of sputum showed an
inconsistent trend across serial samples collected before
and after antibacterial treatment (Figure 6) suggesting
the need for either a larger number of subjects or alter-
native methods for the measurement of live microbes in-
cluding bacteria and fungi. Previous reports in other
body sites have linked antibiotics to increased fungal
burden [82-88]. In a recent study, Dolville et al. [89] in-
vestigated the gut microbiome of mice over 76 days of
treatment with the antibiotics vancomycin, ampicillin,
neomycin, and metronidazole and subsequent recovery.
They observed that bacterial numbers dropped in abun-
dance more than 3-fold while fungi increased ~40-fold
in abundance upon treatment but found that both num-
bers went back to pre-treatment levels upon recovery.
Interestingly, the bacterial microbiome was detectably
different from Candida-free controls and Candida be-
came more abundant than at the time point prior to
treatment [89]. While we observed that fungal density in
sputum had the potential to vary (either increase or de-
crease), we found no common trend. It is important to
note that all of these patients have a significant history
of prior antibiotic exposure and thus some adaptation
may have occurred. The effects of antibiotic therapy in
fungal populations may differ from those obtained upon
first exposure to a drug.
Fungal load has been associated with lung disease se-
verity [16,20,22] suggesting that it is important to meas-
ure fungal density in sputum in addition to the mere
presence of specific species. We found a range of fungal
loads across samples (Figure 6), and this range is consist-
ent with previous reports. For example, Bauernfeind
et al. [15] found between 104 and 107 colony forming
units per gram of sputum of Candida using culture
methods. Charlson et al. [74] highlight the importance
of measuring bacterial and fungal loads and to compare
it to background contamination by upper respiratory
tract flora to identify lung-enriched taxa. Here, we ap-
plied qPCR quantification of the 16S rDNA locus for
total bacteria, the 18S rDNA locus for total fungi, and
species-specific primers to quantify three Candida spe-
cies. One limitation of DNA-based quantification proto-
cols is the inability to differentiate between nucleic acids
from live and dead species. Methods to inactivate DNA
from dead or lysed cells would enhance our understand-
ing of the active microbiota in the lung [90].
Finally, we report the use of VAMPS for analysis of
the ITS1 sequencing results. VAMPS, which has pro-
vided a user-friendly tool for the analysis of bacterial
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communities [2,91], now has an improved database that
will expand the ability to analyze fungal ITS1 sequences
from clinical samples. The VAMPS database, derived from
the UNITE database [58], contains most of the available
ITS1 sequences. However, further curation will improve
taxonomic information in existing entries, and the inclu-
sion of additional high-quality, taxonomically resolved se-
quences that further aid in the analysis and taxon
assignment in future human mycobiome studies [53].
Conclusions
The data presented in this report found stable fungal
communities in the sputum of six individuals with CF.
Though to a lesser extent, stability was also mirrored in
the bacterial communities. We hypothesize that the resi-
dent bacteria have developed a tolerance or resistance to
antimicrobials due to repeated prior exposure, and thus,
little perturbation of co-colonizing fungi is observed. In
addition to numerically dominant fungal populations
that are predominantly members of the genus Candida,
there are less abundant fungi, many of which were less
stable across serial samples from the same subject. To
enhance future analyses of the mycobiome, we devel-
oped and modified a fungal ITS1 database for use in
VAMPS, a publically available tool for the analyses of
visualization of data on microbial communities. Future
studies will continue to investigate the effects of antibac-
terial drugs on fungal and bacterial organisms and their
densities in sputum.
Methods
Study participants and ethics statement
This study was performed in accordance with the guide-
lines set by the Committee for the Protection of Human
Subjects (CPHS) and approved by the Institutional Review
Board (IRB) at Dartmouth College. Sputum samples were
obtained from six subjects over the age of 18 with a con-
firmed diagnosis of CF and who had previous cultures
positive for P. aeruginosa after written, informed consent.
Information about the study participants is provided in
Additional file 1: Table S1.
Sample collection
Serial sputum samples were collected from six CF sub-
jects at the time of hospitalization for treatment of a re-
spiratory disease exacerbation and after a complete
course of intravenous antibacterial therapy, which often
included the use of multiple antibiotics (Additional file 1:
Table S1). For some subjects, an intermediate sample dur-
ing therapy was also collected. Study participants expecto-
rated sputum into a sterile specimen cup, and the sputum
sample was stored at −80°C. In preparation for DNA ex-
traction, the sample was thawed and homogenized by
passing the sputum multiple times through needles of
increasing gauges. Sputum (500 μl) was dispensed into a
2-ml screw cap tube and frozen at −80°C for at least 1 h
prior to lyophilization for at least 12 h. The dry weight of
the sputum was determined before DNA extraction.
DNA extraction
Cells within the dried sputum sample were disrupted
using a mixture sterile glass beads (equivalent amounts
of 0.1-, 0.5-, and 1-mm diameter beads) in a bead beater
(Biospec, Bartlesville, OK, USA); the tubes were agitated
four times for 30 s each time with a cooling step in be-
tween pulses. The ground samples were resuspended in
300 μl of TE + DTT (TE amended with DTT at a final
concentration of 0.08% added from a 2% stock solution)
containing lysozyme (3 mg/ml) and lyticase (10 U/ml)
and incubated for 30 min at 37°C. Cell lysis buffer
(500 μl) (Qiagen Puregene Core Kit B, QIAGEN Inc.,
Valencia, CA, USA) was added, and the mixture was in-
cubated for 15 min at 80°C. To remove RNA, RNase
(1.5 μl) (QIAGEN Inc.) was added and the samples were
incubated for 30 min at 37°C. Lysates were chilled on ice
for 1 min, 200 μl of Protein Precipitation Solution
(Qiagen Puregene Core Kit B, QIAGEN Inc.) was
added, and the solutions were mixed vigorously for
20 s. Cell debris was sedimented by centrifugation at
13,000 rpm for 3 min, and the supernatant was trans-
ferred to a new 1.5-ml tube prior to addition of 600 μl
of 100% isopropanol. After mixing by inversion, the
DNA was precipitated by centrifugation at 13,000 rpm
for 20 min. The DNA pellet was washed with 300 μl of
70% ethanol and air dried before resuspension in 100–
200 μl of DNA hydration solution (Qiagen Puregene
Core Kit B, QIAGEN Inc.). The DNA concentrations
were measured using a Nanodrop.
Fungal ITS1 amplification and sequencing
The ITS1 region was amplified from sputum template
DNA using the primers ITS1F and ITS1R (Additional
file 7: Table S2) in two rounds of PCR. The reaction
components were 1× Qiagen PCR buffer, 0.75 mM
MgCl2, 7% (v/v) dimethyl sulfoxide (DMSO), 0.2 mM
deoxynucleotide triphosphates (dNTPs), 0.4 μM primers,
1.25 units Taq polymerase (QIAGEN Inc.), 100 ng of
template DNA, and water in a 25-μl reaction volume.
Cycling conditions were 95°C 5 min; 95°C 30 s, 50°C
30 s, 72°C 45 s for 10 cycles; and 72°C 2 min. PCR prod-
ucts were purified using the MinElute PCR Purification
Kit (QIAGEN Inc.) and resuspended in 10 μl of EB buf-
fer. The entire 10 μl volume was used as template for a
second round of PCR using primers containing adapter
and barcode sequences for Roche GS-FLX amplicon py-
rosequencing (Additional file 2: Table S2). Reaction
components and cycling conditions were as described
above, but with 30 cycles. Amplified DNA was purified
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with 0.7 volumes of Agencourt AMPure XP beads
(Beckman Coulter, Brea, CA, USA) and quantified on a
Bioanalyzer 2100 (Agilent, Palo Alto, CA, USA). Purified
amplicon libraries were sequenced using the Titanium
amplicon protocol on a GS-FLX (Roche Applied Science,
Indianapolis, IN, USA) following the methods outlined in
[2]. Sequence data were quality filtered as described in
[54,92]. We identified and removed chimeric reads by
querying against the curated reference ITS1 database, as
well as using the sequences as seeds in UCHIME de novo
[93]. The raw sequencing results of the ITS1 analysis
are deposited in the Sequence Read Archive (NCBI Bio-
Project PRJNA246028; National Center for Biotechnology
Information (NCBI), US National Library of Medicine,
Bethesda, MD, USA) and are summarized in Additional
file 5: Table S4.
For the MiSeq analysis of the ITS1 region amplified
from clinical isolates of Candida spp., template DNA
was isolated using the Epicentre Masterpure Yeast DNA
Purification Kit. Primers are listed in Additional file 7:
Table S2. The amplification and sequencing methods
used are comparable to those reported [94].
Bacterial 16S v6 amplification and sequencing
The bacterial communities from the pre- and post-
antibacterial treated CF subjects were characterized by
Illumina HiSeq 16S rRNA V6 amplicon sequencing
(Illumina Inc., San Diego, CA, USA) as previously de-
scribed by Eren et al. [95]. Briefly, we amplified the bac-
terial V6 region from each sample in triplicate 33 μL
reactions, pooled the triplicates, and verified successful
amplification on a Caliper LabChip GX (Perkin Elmer,
Waltham, MA, USA). We cleaned amplicon products
with a QIAQuick clean up assay (QIAGEN Inc.), and
used fusion V6 primers to barcode each sample in a
multiplexing strategy. Final barcoded products were
quantitated with a Picogreen assay (Invitrogen/Life
Technologies, Grand Island, NY, USA) and pooled in
equimolar concentrations with respect to the target
size. All PCR reactions contained 1× HiFi Buffer, 2 mM
MgSO4, 0.02 U/μL Platinum Taq polymerase (Invitro-
gen), 0.2 mM each dNTPs (ThermoFisher Scientific,
Milwaukee, WI, USA), and up to 5 ng template. The
final pool was size selected (Pippin Prep, SageScience,
Beverly, MA, USA), quantitated (Kapa Biosystems, Wo-
burn, MA, USA) and sequenced on a HiSeq 1000 in a
2 × 100 nt sequencing run. Quality filtering and
chimera checks were performed as described above.
The raw sequencing results of the bacterial 16S v6 ana-
lysis are deposited in the Sequence Read Archive (NCBI
BioProject PRJNA256169; National Center for Biotech-
nology Information (NCBI), US National Library of
Medicine, Bethesda, MD, USA) and are summarized in
Additional file 9: Table S6.
Microbiome and mycobiome clustering and taxonomic
assignment
The website http://vamps.mbl.edu provides access to indi-
vidual reads, taxon assignments, and descriptions of indi-
vidual clusters. To create the databases that are accessed
through VAMPS researchers at the Marine Biology Labora-
tories at Woods Hole merged paired-end 100 bp reads into
single consensus reads that completely covered the V6
region, and they assigned taxonomy with GAST [54]
against a curated SILVA database [96]. To compare oper-
ational taxonomic unit (OTU) clustering performance, they
employed the default UCLUST method [97] at a 97% simi-
larity threshold with minimum cluster size of 2 using quan-
titative insights into microbial ecology (QIIME) (v1.5) [98].
Rarefaction analysis
To verify adequate sequencing depth of the mycobiome
and the microbiome, we performed rarefaction analysis
of the two datasets. For both rarefaction analyses, we
used raw counts of all subject samples generated by
VAMPS with the taxonomy depth selector set to “spe-
cies” to create a read matrix. This table was rarefied
using an R-based protocol described on the webpage
“Individual Based Rarefaction using R-package” (http://
www.jennajacobs.org/R/rarefaction.html) [99]. The result-
ing table was transferred into GraphPad Prism 6 to plot
the rarefaction curves.
Euler and Venn diagrams
To visualize the impact of antibacterial treatment on the
prevalence of fungal and bacterial taxa detected in CF
subjects either immediately after an exacerbation and
before starting an antibacterial therapy (pre), approxi-
mately 2 weeks afterwards (post) or while hospitalized
(inter), we used the Additional file 5: Tables S4 and
Additional file 9: Table S6 to generate the diagrams.
First, we copied the data for pre, post and if applicable in-
ter samples into the list-fields of an online Venn diagram
generator (http://www.bioinformatics.lu/venn.php). Using
the R package “RVennDiagram” (http://cran.r-project.org/
web/packages/VennDiagram/index.html), we generated
Euler (“draw.pairwise.venn”) and Venn (“draw.triple.venn”)
diagrams following the instructions in the manual (http://
cran.r-project.org/web/packages/VennDiagram/VennDia-
gram.pdf ).
Quantification of fungi, Candida species, and bacteria
In order to quantify minor members of the mycobiome, we
performed analyses using either sputum DNA or pre-
amplified DNA derived from ten rounds of PCR starting
with 100 ng of sputum DNA using primers specific to a
conserved region of the 18S rDNA (FungiQuant primers)
[100] or Candida species-specific primers (Additional file 7:
Table S2). We confirmed that the pre-amplification step
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was linear with respect to the initial sample; we per-
formed multiple control experiments using genomic
DNA isolated from different fungal species at concen-
trations ranging from 30 pg/μl to 300 ng/μl. The pream-
plification allowed for the analysis of minor members of
the mycobiota. The reaction components of the first PCR
were 1× Qiagen PCR buffer, 0.75 mM MgCl2, 7% (v/v)
DMSO, 0.2 mM dNTPs, 0.4 μM primers, 1.25 units Taq
polymerase (QIAGEN Inc.), 100 ng sputum DNA, and
water in a 25 μl reaction volume. Cycling conditions were
95°C 5 min; 95°C 30 s, 50°C 30 s, 72°C 45 sec for 10 cycles;
and 72°C 2 min. These PCR products were purified using
the MinElute PCR Purification Kit (QIAGEN Inc.), and re-
suspended in 10 μl of EB buffer. Quantitative PCR (qPCR)
was conducted in 20 μl reaction volumes with the iQ
SYBR Green Supermix (Bio-Rad Laboratories, Hercules,
CA, USA). Reactions contained 2 μl of the amplicon
suspension from the first round PCR and 0.2 μM of the
appropriate primers. To quantify total fungal burden,
we used the primers FungiQuant_RT_F and Fungi-
Quant_RT_R [99]. The aforementioned species-specific
qPCR primers were designed to assess Candida burdens
based on gene sequences available from the Candida Gen-
ome Database (http://www.candidagenome.org/). Genes
used for primer design were CAWG_05066 (C. albicans),
CPAR2_301290 (C. parapsilosis), Cd36_16280 (C. dubli-
niensis) and CTRG_03824 (C. tropicalis) and were se-
lected based on conservation within species and a lack of
cross reactivity with bacterial, fungal, and human se-
quences. qPCR was performed utilizing a CFX96 real-time
PCR detection system combined with a C1000 thermal cy-
cler (Bio-Rad Laboratories). All PCRs were done in dupli-
cate, and data were analyzed with the CFX96 System gene
expression software. Melt curve analysis was performed
after the PCR was complete to confirm the absence of
nonspecific amplification products. Standard curves con-
taining a known numbers of genome equivalents were
used to calculate genome numbers per mg dry weight.
For total bacterial quantification, 100 ng of sputum
DNA was used as the PCR reaction template. To gener-
ate a standard curve for quantification purposes we pre-
pared 10-fold dilutions of P. aeruginosa genomic DNA
isolated from 102 to 106 cells. The 16S rDNA genes were
amplified by qPCR, using the universal bacterial primers
“total bacteria_F” and “total bacteria_R” at a final concen-
tration of 0.2 μM [101,102] (Additional file 7: Table S2).
qPCR was conducted in 20 μl reaction volumes with the
iQ SYBR Green Supermix (Bio-Rad Laboratories). qPCRs
for each sputum sample were performed and analyzed on
the CFX96 PCR system as described above.
Statistical analysis
Bray-Curtis dissimilarity was measured using the ecodist
[103] and vegan [104] packages in R statistical software.
Significant differences between groups were established
using analysis of variance with Tukey’s honest significant
difference post-test. Tests producing a P value less than
0.05 were deemed significant. The program Prism 6
(GraphPad, San Diego, CA, USA) was used for remaining
statistical tests.
Additional files
Additional file 1: Table S1. Microbiological results from samples
collected at the time of admission for treatment of exacerbation and
antibacterial drugs administered.
Additional file 2: Figure S1. Analysis of amplification and sequencing
method reproducibility. DNA from a sputum sample was divided,
amplified, sequenced, and analyzed in parallel to evaluate our methods.
Additional file 3: Table S3. Total number of reads used in the
mycobiome (fungi) and the bacterial microbiome analyses.
Additional file 4: Figure S2. Rarefaction analysis of the mycobiome
and microbiome. Rarefaction curves to determine the completeness of
deep sequencing of the mycobiome (A) and the microbiome (B).
Repeated samples of species subsets were used to evaluate whether
further sampling would likely yield additional species, as indicated by
whether the curve has not yet reached a plateau. The y-axis indicates the
number of species detected and the x-axis the number of sequences
analyzed per sample.
Additional file 5: Table S4. Fungal sequences detected in CF sputum
samples using assignments made through VAMPS. The data are
presented as the percent of total reads and absolute read number.
Additional file 6: Table S5. Fungal species within CF sputum samples
using the local BLAST analysis method. The data are normalized to
percent of total reads.
Additional file 7: Table S2. Primer list.
Additional file 8: Figure S3. Principal component analysis based on
Bray-Curtis dissimilarity. Bray-Curtis dissimilarity and principal coordinate
analysis were used to measure and represent taxonomic relatedness
between classes of samples in the mycobiome (fungal taxa) and the
microbiome (bacterial taxa) samples. Pre-treatment samples are colored
in red and are labeled A, intermediate samples collected during treatment
are colored blue and are labeled B, and post-treatment samples are colored
green and are labeled C. The numbers indicate the subject number.
Additional file 9: Table S6. Bacterial genera identified in CF sputum
samples using VAMPS. The data are presented as the percent of total
reads and absolute read number. Only the genera that account for 99%
of all reads are presented.
Additional file 10: Figure S4. Comparison of the normalized richness
of the mycobiome and microbiome. Comparison of the normalized
mean fungal and bacterial richness of pre-treatment and post-treatment
samples. The normalized mean fungal richness shows no significant
difference between treatments (P >0.1) but the normalized mean bacterial
richness decreases upon antibacterial treatment (P <0.05) (Wilcoxon
matched-pairs signed rank test).
Additional file 11: Mycobiome data analysis.
Additional file 12: Figure S5. Bacterial communities within a subject
before, during, and after treatment. Distribution of bacterial taxa detected
in CF subjects either immediately after an exacerbation and before
starting an antibacterial therapy (pre), approximately 2 weeks afterwards
(post) or while hospitalized (inter) presented in Euler diagrams for the
pre- and post-samples (subjects #1–6) and Venn diagrams for series with
three samples (subjects #8 and 9). The numbers in parenthesis describe
the total number of taxa detected in a sample; the numbers in the circles
represent either the unique number of taxa in a sample or the number
of shared taxa in the overlap regions.
Additional file 13: Table S7. Summary of fungal taxa found in more
than one sample.
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Additional file 14: Figure S6. Quantification of total fungi and specific
Candida species in sputum of CF subjects. Quantification of the fungal
burden of sputum samples from CF subjects. Fungal burden was
determined by amplifying the 18S rDNA locus by qPCR. For Candida
species-specific quantification, we used the genes CAWG_05066 (C. albicans),
CPAR2_301290 (C. parapsilosis), and Cd36_16280 (C. dubliniensis). Fungal
genome copy number was determined by comparison to a standard curve
generated using DNA isolated from pure cultures of Candida albicans as
described in the methods.
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